These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 16951018

  • 1. Stimulants and sudden death: what is a physician to do?
    Wilens TE, Prince JB, Spencer TJ, Biederman J.
    Pediatrics; 2006 Sep; 118(3):1215-9. PubMed ID: 16951018
    [Abstract] [Full Text] [Related]

  • 2. Cardiovascular safety of medication treatments for attention-deficit/hyperactivity disorder.
    Newcorn JH, Donnelly C.
    Mt Sinai J Med; 2009 Apr; 76(2):198-203. PubMed ID: 19306385
    [No Abstract] [Full Text] [Related]

  • 3. Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder.
    Winterstein AG, Gerhard T, Shuster J, Johnson M, Zito JM, Saidi A.
    Pediatrics; 2007 Dec; 120(6):e1494-501. PubMed ID: 18055666
    [Abstract] [Full Text] [Related]

  • 4. Stimulant-drug therapy for attention-deficit disorder (with or without hyperactivity) and sudden cardiac death.
    Knight M.
    Pediatrics; 2007 Jan; 119(1):154-5. PubMed ID: 17200281
    [No Abstract] [Full Text] [Related]

  • 5. Cardiovascular risk screening before starting stimulant medications and prescribing practices of canadian physicians: impact of the Health Canada advisory.
    Conway J, Wong KK, O'Connell C, Warren AE.
    Pediatrics; 2008 Oct; 122(4):e828-34. PubMed ID: 18829780
    [Abstract] [Full Text] [Related]

  • 6. [Medication for ADHD and the risk of cardiovascular mortality].
    Kalverdijk LJ, Buitelaar JK, van der Gaag RJ.
    Ned Tijdschr Geneeskd; 2006 Oct 14; 150(41):2283-4; author reply 2284. PubMed ID: 17078147
    [No Abstract] [Full Text] [Related]

  • 7. [Medication for ADHD and the risk of cardiovascular mortality].
    Langendijk PN, Wilde AA.
    Ned Tijdschr Geneeskd; 2006 Aug 05; 150(31):1713-4. PubMed ID: 16924941
    [Abstract] [Full Text] [Related]

  • 8. Medications for attention deficit hyperactivity disorder: cardiovascular concerns.
    Wooltorton E.
    CMAJ; 2006 Jul 04; 175(1):29. PubMed ID: 16772535
    [No Abstract] [Full Text] [Related]

  • 9. ECGs before stimulants in children.
    Med Lett Drugs Ther; 2008 Jul 28; 50(1291):60. PubMed ID: 18654112
    [No Abstract] [Full Text] [Related]

  • 10. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder.
    Perrin JM, Friedman RA, Knilans TK, Black Box Working Group, Section on Cardiology and Cardiac Surgery.
    Pediatrics; 2008 Aug 28; 122(2):451-3. PubMed ID: 18676566
    [No Abstract] [Full Text] [Related]

  • 11. [Cardiovascular risk assessment for the use of ADHD drugs in children].
    Berg A, Bråtane E, Odland HH, Brudvik C, Rosland B, Hirth A.
    Tidsskr Nor Laegeforen; 2014 Apr 08; 134(7):710-4. PubMed ID: 24721858
    [Abstract] [Full Text] [Related]

  • 12. A controlled study of autonomic nervous system function in adults with attention-deficit/hyperactivity disorder treated with stimulant medications: results of a pilot study.
    Schubiner H, Hassunizadeh B, Kaczynski R.
    J Atten Disord; 2006 Nov 08; 10(2):205-11. PubMed ID: 17085631
    [Abstract] [Full Text] [Related]

  • 13. Cardiovascular risk of stimulant treatment in pediatric attention-deficit/hyperactivity disorder: update and clinical recommendations.
    Hammerness PG, Perrin JM, Shelley-Abrahamson R, Wilens TE.
    J Am Acad Child Adolesc Psychiatry; 2011 Oct 08; 50(10):978-90. PubMed ID: 21961773
    [Abstract] [Full Text] [Related]

  • 14. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
    Chavez B, Sopko MA, Ehret MJ, Paulino RE, Goldberg KR, Angstadt K, Bogart GT.
    Ann Pharmacother; 2009 Jun 08; 43(6):1084-95. PubMed ID: 19470858
    [Abstract] [Full Text] [Related]

  • 15. Attention-deficit-hyperactivity disorder: an update.
    Dopheide JA, Pliszka SR.
    Pharmacotherapy; 2009 Jun 08; 29(6):656-79. PubMed ID: 19476419
    [Abstract] [Full Text] [Related]

  • 16. Cardiovascular safety of stimulant medications for pediatric attention-deficit hyperactivity disorder.
    Silva RR, Skimming JW, Muniz R.
    Clin Pediatr (Phila); 2010 Sep 08; 49(9):840-51. PubMed ID: 20693523
    [Abstract] [Full Text] [Related]

  • 17. Growth and sexual maturation in children and adolescents with attention deficit hyperactivity disorder.
    Poulton A.
    Curr Opin Pediatr; 2006 Aug 08; 18(4):427-34. PubMed ID: 16914999
    [Abstract] [Full Text] [Related]

  • 18. [Cardiovascular risks and management during Attention Deficit Hyperactivity Disorder treatment with methylphenidate].
    Bange F, Le Heuzey MF, Acquaviva E, Delorme R, Mouren MC.
    Arch Pediatr; 2014 Jan 08; 21(1):108-12. PubMed ID: 24309201
    [Abstract] [Full Text] [Related]

  • 19. Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.
    Martinez-Raga J, Knecht C, Szerman N, Martinez MI.
    CNS Drugs; 2013 Jan 08; 27(1):15-30. PubMed ID: 23160939
    [Abstract] [Full Text] [Related]

  • 20. National estimates and factors associated with medication treatment for childhood attention-deficit/hyperactivity disorder.
    Visser SN, Lesesne CA, Perou R.
    Pediatrics; 2007 Feb 08; 119 Suppl 1():S99-106. PubMed ID: 17272592
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.